Phase III trial for Romark's influenza drug underway

04/22/2013 | Pharmaceutical Business Review Online

Romark Laboratories has started patient enrollment for a late-stage study of its influenza drug NT-300, or nitazoxanide. The study will involve 1,400 patients with fever and other flu symptoms. The trial is expected to be finished during the 2013-2014 flu season.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA